CSL share price plunges 8% as profit guidance slashed

ASX 200 investors are hitting the sell button on CSL shares amid a profit guidance downgrade.

| More on:
Scientists in white coats look disappointed as the Starpharma share price falls today

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Ltd (ASX: CSL) share price is falling hard today, down 8.28% right now.

Shares in the S&P/ASX 200 Index biotechnology company closed yesterday trading for $308.52. At the time of writing, shares are swapping hands for $282.98.

Here's what ASX 200 investors are considering today.

What did the ASX 200 biotech stock report?

The CSL share price is tumbling after the company updated the market on the impact of foreign currency movements on its 2023 financial year (FY23) profit forecast.

CSL's FY23 profit forecast was reduced due to higher-than-expected foreign currency headwinds of some US$230 million to US$250 million. CSL had previously forecast an impact of US$175 million when it reported its half-year results.

The company's constant currency profit guidance for FY23 remains the same.

As for FY24, having finalised its budget for the year, CSL expects net profits after tax and amortisation (NPATA) to increase by 13% to 18%, or approximately US$2.9 billion to US$3.0 billion at constant currency.

While that's a decent year-on-year growth in NPATA, RBC Capital expected the CSL share price would take a hit from its FY24 profit guidance (courtesy of The Australian Financial Review).

That's because it comes in below consensus expectations of US$3.5 billion and well below RBC's own forecast of US$3.8 billion.

CSL share price snapshot

The CSL share price has been a strong outperformer, gaining 9% over the past 12 months despite today's slide.

Year to date, the ASX 200 biotech stock remains up 2%.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

3 ASX 200 healthcare stocks that could deliver big returns for investors

Analysts see a lot of value in these stocks at current levels.

Read more »

A team of people giving the thumbs up sign representing APA and Wesfarmers doing a deal to study green hydrogen transport using an APA gas pipeline
Healthcare Shares

Why are so many top fundies overweight on CSL shares?

This is a healthy opportunity, according to a number of fund managers.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Share Fallers

Why did this ASX All Ords stock just crash 16%?

Investors are punishing this ASX All Ords stock on Thursday. But why?

Read more »

woman in lab coat conducting testing representing biotech
Healthcare Shares

Can the CSL share price really reach $500 in just 3 years?

Leading analysts are expecting big returns from CSL shares in the months ahead.

Read more »

Two businesspeople walk together in an office, smiling as they enjoy a good business relationship.
Healthcare Shares

Why two brokers have named this ASX 200 stock as a best buy

Investors may want to pounce on this high-quality stock before it's too late.

Read more »

A young man goes over his finances and investment portfolio at home.
Healthcare Shares

What could $5,000 invested in CSL shares become in 1 year?

Let's see what sort of returns analysts are tipping for this ASX giant.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Why is everyone talking about Mesoblast shares?

ASX biotech share Mesoblast has been grabbing plenty of investor attention recently.

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Why the Mesoblast share price can rise another 60%

The big gains may not be over according to Bell Potter.

Read more »